• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WU Congyu, ZHOU Yue, SHANGGUAN Luxi, YANG Yani, WANG Jingya, YU Junhe, GONG Shuaishuai, KOU Junping. Progress of research on the pharmacological effects and mechanisms of emodin[J]. Journal of China Pharmaceutical University, 2023, 54(5): 634-643. DOI: 10.11665/j.issn.1000-5048.2023052501
Citation: WU Congyu, ZHOU Yue, SHANGGUAN Luxi, YANG Yani, WANG Jingya, YU Junhe, GONG Shuaishuai, KOU Junping. Progress of research on the pharmacological effects and mechanisms of emodin[J]. Journal of China Pharmaceutical University, 2023, 54(5): 634-643. DOI: 10.11665/j.issn.1000-5048.2023052501
shu

Progress of research on the pharmacological effects and mechanisms of emodin

  • Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Pharmacy, Jiangsu Key Laboratory of Traditional Chinese Medicine Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Innovation and Entrepreneurship Training Program for Undergraduate（No.202310316014Z）
More Information
  • Received Date: May 24, 2023
  • Revised Date: October 17, 2023
    Graphical Abstract
    • Abstract
  • As an active hydroxyanthraquinone ingredient, emodin is abundant in Chinese medicine herbs, such as Rheum palmatum, Polygonum cuspidatum and Polygonum multiflorum.Modern pharmacological studies have shown that emodin has a variety of pharmacological activities including anti-tumor, anti-inflammatory and immunoregulatory, antibacterial and anti-viral effects, myocardial protection, neuroprotection, renal protection, bone protection, antifibrosis and so on, which indicate its high medicinal value and broad application prospects.This article aims to summarize the progress in the pharmacological activity and mechanism of action of emodin published in domestic and international journals over the last 5 years and highlight the potential targets and molecular signaling pathways linked with emodin, so as to provide some clues and references for further development and clinical application of emodin.
    • FullText(HTML)
    • References (80)
  • [1]
    Mitra S, Anjum J, Muni M, et al. Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action[J]. Biomed Pharmacother, 2022, 149: 112877.
    [2]
    HaoShang, Jia XH, Liu HM, et al. A comprehensive review of emodin in fibrosis treatment[J]. Fitoterapia, 2023, 165: 105358.
    [3]
    Xing XY, Wang XC, He W. Advances in research on tumor immunotherapy and its drug development[J]. J China Pharm Univ (中国药科大学学报), 2021, 52(1): 10-19.
    [4]
    Forma E, Bry? M. Anticancer activity of Propolis and its compounds[J]. Nutrients, 2021, 13(8): 2594.
    [5]
    Saunders IT, Mir H, Kapur N, et al. Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways[J]. Cancer Cell Int, 2019, 19: 98.
    [6]
    Zhang N, Wang JW, Sheng AM, et al. Emodin inhibits the proliferation of MCF-7 human breast cancer cells through activation of aryl hydrocarbon receptor (AhR)[J]. Front Pharmacol, 2020, 11: 622046.
    [7]
    Li MZ, Jin SB, Cao Y, et al. Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated moti-lity (RHAMM) interaction-dependent signaling pathway[J]. Cancer Cell Int, 2021, 21(1): 19.
    [8]
    Tong HF, Huang Z, Chen H, et al. Emodin reverses gemcitabine resistance of pancreatic cancer cell lines through inhibition of IKKβ/NF-κB signaling pathway[J]. Onco Targets Ther, 2020, 13: 9839-9848.
    [9]
    Zhang FY, Li RZ, Xu C, et al. Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa[J]. Phytomedicine, 2022, 95: 153786.
    [10]
    Qin BY, Zeng ZL, Xu JL, et al. Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin[J]. BMC Cancer, 2022, 22(1): 671.
    [11]
    Ponnusamy L, Kothandan G, Manoharan R. Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(11): 165897.
    [12]
    Jiang J, Zhou NY, Ying P, et al. Emodin promotes apoptosis of human endometrial cancer through regulating the MAPK and PI3K/AKT pathways[J]. Open Life Sci, 2018, 13: 489-496.
    [13]
    Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; The three main axes of metastasis[J]. Biomedecine Pharmacother, 2021, 133: 110909.
    [14]
    Li N, Wang CL, Zhang P, et al. Emodin inhibits pancreatic cancer EMT and invasion by up-regulating microRNA-1271[J]. Mol Med Rep, 2018, 18(3): 3366-3374.
    [15]
    Liu Q, Hodge J, Wang JF, et al. Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation[J]. Theranostics, 2020, 10(18): 8365-8381.
    [16]
    Gu J, Cui CF, Yang L, et al. Emodin inhibits colon cancer cell invasion and migration by suppressing epithelial-mesenchymal transition via the Wnt/β-catenin pathway[J]. Oncol Res, 2019, 27(2): 193-202.
    [17]
    Yin J, Zhao XS, Chen XJ, et al. Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B[J]. Bioengineered, 2022, 13(4): 9548-9563.
    [18]
    Dai GL, Wang D, Ma ST, et al. ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin[J]. Phytomedicine, 2022, 102: 154149.
    [19]
    Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives[J]. Cell Oncol, 2021, 44(4): 715-737.
    [20]
    Zou GY, Zhang XT, Wang L, et al. Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription[J]. Theranostics, 2020, 10(15): 6839-6853.
    [21]
    Shi GH, Zhou L. Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6-mediated pathways in vivo and in vitro[J]. Mol Med Rep, 2018, 18(6): 5191-5197.
    [22]
    Deng ZY, Liu SY. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases[J]. Drug Deliv Transl Res, 2021, 11(4): 1475-1497.
    [23]
    Mei HX, Tao Y, Zhang TH, et al. Emodin alleviates LPS-induced inflammatory response in lung injury rat by affecting the function of granulocytes[J]. J Inflamm, 2020, 17: 26.
    [24]
    Xie P, Yan LJ, Zhou HL, et al. Emodin protects against lipopolysaccharide-induced acute lung injury via the JNK/Nur77/c-Jun signaling pathway[J]. Front Pharmacol, 2022, 13: 717271.
    [25]
    Li XQ, Shan C, Wu ZH, et al. Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway[J]. Inflamm Res, 2020, 69(4): 365-373.
    [26]
    Wu XJ, Yao JQ, Hu Q, et al. Emodin ameliorates acute pancreatitis-associated lung injury through inhibiting the alveolar macrophages pyroptosis[J]. Front Pharmacol, 2022, 13: 873053.
    [27]
    Zhang QK, Tao XF, Xia SL, et al. Emodin attenuated severe acute pancreatitis via the P2X ligand-gated ion channel7/NOD-like receptor protein3 signaling pathway[J]. Oncol Rep, 2019, 41(1): 270-278.
    [28]
    Lin J, Ma C, Lin H. Emodin alleviates viral myocarditis in BALB/c mice and underlying mechanisms[J]. Lat Am J Pharm, 2019, 38(10): 1979-1984.
    [29]
    Luo S, Deng XL, Liu Q, et al. Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice[J]. Int Immunopharmacol, 2018, 59: 269-275.
    [30]
    Reijnders TDY, Saris A, Schultz MJ, et al. Immunomodulation by macrolides: therapeutic potential for critical care[J]. Lancet Respir Med, 2020, 8(6): 619-630.
    [31]
    Cui YR, Bu ZQ, Yu HY, et al. Emodin attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis[J]. Neural Regen Res, 2023, 18(7): 1535-1541.
    [32]
    Zheng KN, Lv BJ, Wu LL, et al. Protecting effect of emodin in experimental autoimmune encephalomyelitis mice by inhibiting microglia activation and inflammation via Myd88/PI3K/Akt/NF-κB signalling pathway[J]. Bioengineered, 2022, 13(4): 9322-9344.
    [33]
    Ding Y, Xu J, Cheng LB, et al. Effect of emodin on coxsackievirus B3m-mediated encephalitis in hand, foot, and mouth disease by inhibiting toll-like receptor 3 pathway in vitro and in vivo[J]. J Infect Dis, 2020, 222(3): 443-455.
    [34]
    Mabwi HA, Lee HJ, Hitayezu E, et al. Emodin modulates gut microbial community and triggers intestinal immunity[J]. J Sci Food Agric, 2023, 103(3): 1273-1282.
    [35]
    Zhou Q, Xiang H, Liu H, et al. Emodin alleviates intestinal barrier dysfunction by inhibiting apoptosis and regulating the immune response in severe acute pancreatitis[J]. Pancreas, 2021, 50(8): 1202-1211.
    [36]
    Huy TXN, Reyes AWB, Hop HT, et al. Emodin successfully inhibited invasion of Brucella abortus via modulting adherence, microtubule dynamics and ERK signaling pathway in RAW 264.7 cells[J]. J Microbiol Biotechnol, 2018, 28(10): 1723-1729.
    [37]
    Gao RJ, Wang CJ, Han A, et al. Emodin improves intestinal health and immunity through modulation of gut microbiota in mice infected by pathogenic Escherichia coli O1[J]. Animals, 2021, 11(11): 3314.
    [38]
    Bei YF, Tia BY, Li YZ, et al. Anti-influenza A virus effects and mechanisms of emodin and its analogs via regulating PPARα/γ-AMPK-SIRT1 pathway and fatty acid metabolism[J]. Biomed Res Int, 2021, 2021: 9066938.
    [39]
    Xu ZC, Huang MY, Xia YB, et al. Emodin from Aloe inhibits Porcine reproductive and respiratory syndrome virus via Toll-like receptor 3 activation[J]. Viruses, 2021, 13(7): 1243.
    [40]
    Rolta R, Kumar V, Sourirajan A, et al. Bioassay guided fractionation of rhizome extract of Rheum emodi wall as bio-availability enhancer of antibiotics against bacterial and fungal pathogens[J]. J Ethnopharmacol, 2020, 257: 112867.
    [41]
    Batista MN, Braga ACS, Campos GRF, et al. Natural products isolated from oriental medicinal herbs inactivate zika virus[J]. Viruses, 2019, 11(1): 49.
    [42]
    Guo YY, Zhang RZ, Li WL. Emodin in cardiovascular disease: the role and therapeutic potential[J]. Front Pharmacol, 2022, 13: 1070567.
    [43]
    Wang XJ, Zhang L, Feng MW, et al. ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK/MAPK and PI3K/AKT signaling pathways[J]. Front Pharmacol, 2022, 13: 873614.
    [44]
    Liu JF, Ning L. Protective role of emodin in rats with post-myocardial infarction heart failure and influence on extracellular signal-regulated kinase pathway[J]. Bioengineered, 2021, 12(2): 10246-10253.
    [45]
    Zhang XZ, Qin QJ, Dai HY, et al. Emodin protects H9c2 cells from hypoxia-induced injury by up-regulating miR-138 expression[J]. Braz J Med Biol Res, 2019, 52(3): e7994.
    [46]
    Hou K, Tan HY, Liu J, et al. Advance of novel target strategies participating in myocardial ischemia reperfusion injury[J]. J China Pharm Univ (中国药科大学学报), 2022, 53(2): 164-170.
    [47]
    Ye BZ, Chen XD, Dai SS, et al. Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes[J]. Drug Des Devel Ther, 2019, 13: 975-990.
    [48]
    Zhang XZ, Qin QJ, Lv XH, et al. Natural emodin reduces myocardial ischemia/reperfusion injury by modulating the RUNX1/miR-142-3p/DRD2 pathway and attenuating inflammation[J]. Exp Ther Med, 2022, 24(6): 745.
    [49]
    Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy[J]. Circ Res, 2021, 128(10): 1533-1553.
    [50]
    Gao J, Zhang KL, Wang Y, et al. A machine learning-driven study indicates emodin improves cardiac hypertrophy by modulation of mitochondrial SIRT3 signaling[J]. Pharmacol Res, 2020, 155: 104739.
    [51]
    Evans LW, Bender A, Burnett L, et al. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy[J]. J Nutr Biochem, 2020, 79: 108339.
    [52]
    Evans L, Shen Y, Bender A, et al. Divergent and overlapping roles for selected phytochemicals in the regulation of pathological cardiac hypertrophy[J]. Molecules, 2021, 26(5): 1210.
    [53]
    Chen Q, Lai CC, Chen F, et al. Emodin protects SH-SY5Y cells against zinc-induced synaptic impairment and oxidative stress through the ERK1/2 pathway[J]. Front Pharmacol, 2022, 13: 821521.
    [54]
    Leung SW, Lai JH, Wu JCC, et al. Neuroprotective effects of emodin against ischemia/reperfusion injury through activating ERK-1/2 signaling pathway[J]. Int J Mol Sci, 2020, 21(8): 2899.
    [55]
    Du CW, Shi LN, Wang M, et al. Emodin attenuates Alzheimer’s disease by activating the protein kinase C signaling pathway[J]. Cell Mol Biol, 2019, 65(5): 32-37.
    [56]
    Li ZP, Bi H, Jiang HB, et al. Neuroprotective effect of emodin against Alzheimer’s disease via Nrf2 signaling in U251cells and APP/PS1 mice[J]. Mol Med Rep, 2021, 23(2): 108.
    [57]
    Zeng P, Shi Y, Wang XM, et al. Emodin rescued hyperhomocysteinemia-induced dementia and Alzheimer’s disease-like features in rats[J]. Int J Neuropsychopharmacol, 2019, 22(1): 57-70.
    [58]
    Sim?es Da Gama C, Morin-Brureau M. Study of BBB dysregulation in neuropathogenicity using integrative human model of blood-brain barrier[J]. Front Cell Neurosci, 2022, 16: 863836.
    [59]
    Li Y, Xu QQ, Shan CS, et al. Combined use of emodin and ginsenoside Rb1 exerts synergistic neuroprotection in cerebral ischemia/reperfusion rats[J]. Front Pharmacol, 2018, 9: 943.
    [60]
    Lv BJ, Zheng KN, Sun YF, et al. Network pharmacology experiments show that emodin can exert a protective effect on MCAO rats by regulating Hif-1α/VEGF-A signaling[J]. ACS Omega, 2022, 7(26): 22577-22593.
    [61]
    Sun L, Han YQ, Shen CQ, et al. Emodin alleviates high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation of mesangial cells by the circ_0000064/miR-30c-5p/Lmp7 axis[J]. J Recept Signal Transduct Res, 2022, 42(3): 302-312.
    [62]
    Fu SJ, Zhou YN, Hu C, et al. Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy[J]. BMC Complement Med Ther, 2022, 22(1): 210.
    [63]
    Wang YQ, Liu Q, Cai JY, et al. Emodin prevents renal ischemia-reperfusion injury via suppression of CAMKII/DRP1-mediated mitochondrial fission[J]. Eur J Pharmacol, 2022, 916: 174603.
    [64]
    Liu Y, Li MQ, Teh L, et al. Emodin-mediated treatment of acute kidney injury[J]. Evid Based Complement Alternat Med, 2022, 2022: 5699615.
    [65]
    Aspray TJ, Hill TR. Osteoporosis and the ageing skeleton[J]. Subcell Biochem, 2019, 91: 453-476.
    [66]
    Luo JS, Zhao XH, Yang Y. Effects of emodin on inflammatory bowel disease-related osteoporosis[J]. Biosci Rep, 2020, 40(1): BSR20192317.
    [67]
    Ding QH, Ye CY, Chen EM, et al. Emodin ameliorates cartilage degradation in osteoarthritis by inhibiting NF-κB and Wnt/β-catenin signaling in-vitro and in-vivo[J]. Int Immunopharmacol, 2018, 61: 222-230.
    [68]
    Liu ZF, Lang Y, Li L, et al. Effect of emodin on chondrocyte viability in an in vitro model of osteoarthritis[J]. Exp Ther Med, 2018, 16(6): 5384-5389.
    [69]
    Liang BY, Gao LY, Wang FX, et al. The mechanism research on the anti-liver fibrosis of emodin based on network pharmacology[J]. IUBMB Life, 2021, 73(9): 1166-1179.
    [70]
    Yao H, He QM, Huang C, et al. Panaxatriol saponin ameliorates myocardial infarction-induced cardiac fibrosis by targeting Keap1/Nrf2 to regulate oxidative stress and inhibit cardiac-fibroblast activation and proliferation[J]. Free Radic Biol Med, 2022, 190: 264-275.
    [71]
    Carver W, Fix E, Fix C, et al. Effects of emodin, a plant-derived anthraquinone, on TGF-β1-induced cardiac fibroblast activation and function[J]. J Cell Physiol, 2021, 236(11): 7440-7449.
    [72]
    Xiao D, Zhang Y, Wang R, et al. Emodin alleviates cardiac fibrosis by suppressing activation of cardiac fibroblasts via upregulating metastasis associated protein 3[J]. Acta Pharm Sin B, 2019, 9(4): 724-733.
    [73]
    Yang J, Jiang GD, Ni KW, et al. Emodin inhibiting epithelial-mesenchymal transition in pulmonary fibrosis through the c-MYC/miR-182-5p/ZEB2 axis[J]. Phytother Res, 2023, 37(3): 926-934.
    [74]
    Pang XR, Shao LL, Nie XJ, et al. Emodin attenuates silica-induced lung injury by inhibition of inflammation, apoptosis and epithelial-mesenchymal transition[J]. Int Immunopharmacol, 2021, 91: 107277.
    [75]
    Zhou LS, Gao RD, Hong HH, et al. Emodin inhibiting neutrophil elastase-induced epithelial-mesenchymal transition through Notch1 signalling in alveolar epithelial cells[J]. J Cell Mol Med, 2020, 24(20): 11998-12007.
    [76]
    Liu XZ, Song B, Zhang HQ, et al. The effects of emodin on insulin resistance in KKAy mice with diabetes mellitus[J]. Pharmacogn Mag, 2018, 14(56): 344.
    [77]
    Xiao D, Hu YY, Fu YJ, et al. Emodin improves glucose metabolism by targeting microRNA-20b in insulin-resistant skeletal muscle[J]. Phytomedicine, 2019, 59: 152758.
    [78]
    Xiong XL, Ding Y, Chen ZL, et al. Emodin rescues intrahepatic cholestasis via stimulating FXR/BSEP pathway in promoting the canalicular export of accumulated bile[J]. Front Pharmacol, 2019, 10: 522.
    [79]
    Wang SX, Kong X, Chen N, et al. Hepatotoxic metabolites in Polygoni multiflori radix- comparative toxicology in mice[J]. Front Pharmacol, 2022, 13: 1007284.
    [80]
    Sun J, Xu ZS, Hou Y, et al. Hierarchically structured microcapsules for oral delivery of emodin and tanshinone IIA to treat renal fibrosis[J]. Int J Pharm, 2022, 616: 121490.
    • Related Articles

  • Related Articles

    [1]WANG Lele, QIANG Weijie, WANG Jianjun, GE Weihong. Research progress of pharmacological actions and clinical applications of diterpene ginkgolides meglumine injection[J]. Journal of China Pharmaceutical University, 2024, 55(6): 837-844. DOI: 10.11665/j.issn.1000-5048.2023110601
    [2]LU Ningshu, JI Tao, LU Yinglan, XU Xiyuan, GU Xiaochen, DING Yang. Drug delivery strategies and clinical research progress for encephalopathy[J]. Journal of China Pharmaceutical University, 2024, 55(5): 577-589. DOI: 10.11665/j.issn.1000-5048.2024063001
    [3]WANG Chen, ZHANG Zhengping, LI Yinchun. Development strategy and clinical research progress of universal chimeric antigen receptor T-cell drugs[J]. Journal of China Pharmaceutical University, 2023, 54(2): 141-149. DOI: 10.11665/j.issn.1000-5048.20211125001
    [4]WANG Jingqi, WANG Ye, ZHANG Yi, LIANG Juncheng, DENG Yanping, HANG Taijun, SONG Min. Metabolomic study on clinical staging of methamphetamine detoxification by LC-QTOF-MS[J]. Journal of China Pharmaceutical University, 2022, 53(3): 314-322. DOI: 10.11665/j.issn.1000-5048.20220309
    [5]LIU Yuhong, ZHANG Fangfang, LIU Jianxing, LIU Yue, YANG Yue, JIN Liang. Interplay between non-coding RNA and insulin signaling pathway and its clinical application[J]. Journal of China Pharmaceutical University, 2021, 52(3): 279-286. DOI: 10.11665/j.issn.1000-5048.20210303
    [6]YIN Kunpeng, ZHENG Hao, XIE Binxin, LI Ping, ZHANG Lei, FAN Yong, ZHU Wei, QI Lianwen. Clinical metabolomics in diagnosis and therapy of coronary artery disease[J]. Journal of China Pharmaceutical University, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601
    [7]TAN Chengning, HUANG Jinghan, LI Chunhong, XIA Zhining, YANG Fengqing. Applications of proteomics in the study of cell signal pathways[J]. Journal of China Pharmaceutical University, 2017, 48(4): 384-395. DOI: 10.11665/j.issn.1000-5048.20170402
    [8]HAO Kun, YU Dan, WANG Guangji. Pharmacokinetic translational research from bench to bedside[J]. Journal of China Pharmaceutical University, 2015, 46(1): 50-57. DOI: 10.11665/j.issn.1000-5048.20150105
    [9]LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603
    [10]Using Advanced eCDM Technology to Improve Clinical Trial Efficiency[J]. Journal of China Pharmaceutical University, 2004, (4): 1-4.

  • Cited by

    Periodical cited type(23)

    1. 邵文鹤，王想福，陈伟国，赵恒，张万乾，谢芋涛，陶瑜晶，任毅，杨建霞，杨鹏程. 中医药干预NLRP3炎症小体治疗椎间盘退变的研究进展. 中医学报. 2025(02): 349-356 .
    2. 陈文芃，魏丹蕾，林春挺，杨晓晴. 补阳活络肾宁饮联合西医基础疗法治疗Mogensen分期Ⅲ～Ⅳ期糖尿病肾病患者的疗效及对肾功能的影响. 临床和实验医学杂志. 2025(01): 33-38 .
    3. 王湘臻，袁培，王庆明. 解毒敛疮膏联合封闭式负压引流技术治疗深Ⅱ度烧伤创面的临床研究. 现代生物医学进展. 2025(02): 289-294 .
    4. 李袁袁，钟旋，刘磊，孙淑亚，凌家俊，林荣锋. 大承气汤通过内源性抗菌肽mCRAMP对脓毒症小鼠肠屏障的保护作用及机制. 中国实验方剂学杂志. 2024(06): 20-28 .
    5. 江轶伦，张慧林，练剑锋. 八正散合少腹逐瘀汤加减联合左氧氟沙星胶囊治疗湿热瘀阻型慢性前列腺炎的研究. 中医研究. 2024(02): 46-49 .
    6. 江波，祝庆岭，徐寰，刘涛，盛炎炎，李文华. 复元活血汤加减联合经皮椎体后凸成形术治疗OVCF临床疗效观察. 内蒙古中医药. 2024(03): 5-8 .
    7. 陈巧毅，胡丽燕，徐艳. 百令胶囊联合大黄碳酸氢钠片治疗尿毒症维持血液透析患者临床研究. 新中医. 2024(06): 90-94 .
    8. 张爽，毕映燕，刘晓婷，宫玉锁，刘学睿，元宝华，禄成龙，陈绪帆，王莹，光佳如. 中药有效成分调控氧化应激防治骨关节炎的研究进展. 中国实验方剂学杂志. 2024(11): 282-289 .
    9. 谭佳妮，王忠良. 中药材大黄浸出液干预大鼠急性放射性口腔黏膜炎的效果观察. 生物化工. 2024(02): 100-103 .
    10. 姚彬，王占魁，康武林，董佩，白元帅，陈永程，袁普卫. 中医药调控氧化应激治疗骨关节炎的研究进展. 中医正骨. 2024(05): 54-60 .
    11. 楚建设. 加味茵陈蒿汤辅助肝动脉化疗栓塞术对中晚期原发性肝癌患者中医证候和Janus激酶2/信号转导与转录激活因子3信号通路的影响. 河北中医. 2024(09): 1450-1454+1459 .
    12. 李梦，陈波，吴娟. 大黄素调节NLRP3/IL-1β/CXCL1信号通路改善急性呼吸衰竭大鼠炎症反应和肺损伤的实验研究. 中国中医急症. 2024(08): 1349-1353+1386 .
    13. 张燕良. 厚朴排气合剂联合甲氧氯普胺治疗不完全性肠梗阻的临床应用观察. 医学理论与实践. 2024(17): 2941-2943 .
    14. 姜萌，郝淑兰，仝立国，冯玛莉，刘丽坤，王晞星，吉海杰. 复方藤芷凝胶贴膏剂制备工艺及透皮主要成分研究. 辽宁中医药大学学报. 2024(09): 57-63 .
    15. 单兰，宋芳蕾，陈媛媛. 纳子法指导下金龙硝黄散择时外敷联合胸腔灌注治疗恶性胸腔积液的临床研究. 中华养生保健. 2024(17): 9-13 .
    16. 时鑫，李永静，郝立校，龚彪，丛军. ERCP联合健脾清胆汤治疗PH1儿童肝移植术后吻合口狭窄合并化脓性胆管炎伴胆汁瘤1例. 中国中西医结合消化杂志. 2024(09): 825-829 .
    17. 车楠，李裕，高一点，张茹悦，邬金江，柳来栓，董秀芳，裴江峰，姜一凡，胡义文. 丹蒽醌-镁配合物的模拟计算、合成及抗老化性能. 化学研究与应用. 2024(09): 2095-2101 .
    18. 史雯馨 ，周锦航 ，邵仕娟 ，蔡羽 ，陈运中 . 基于高效液相色谱指纹图谱的不同采收期虎杖叶的区分及多成分含量的测定. 理化检验-化学分册. 2024(10): 986-992 .
    19. 曹姗，耿子涵，包蕾，徐英莉，庞博，张敬升，张宇，陈梦苹，王雅欣，赵荣华，郭姗姗，崔晓兰. 甲型流感病毒对人肺上皮细胞BEAS-2B的影响及疏风解毒胶囊含药血清的干预作用. 中国实验方剂学杂志. 2024(23): 90-97 .
    20. 刘振航，谢婷，张凯，李娜，陈扬波. 解毒泻肺合剂治疗老年重症肺炎（痰热壅肺证）临床观察. 中国中医急症. 2024(10): 1773-1776 .
    21. 陈伟，龚碧娇，陈晓英，徐才剑. 肺瘅宁方治疗社区获得性肺炎（痰热壅肺证）临床观察. 中国中医急症. 2024(10): 1808-1810 .
    22. 曹定娅，武晓娟，付婷婷，宋兵. 大黄素对感染性早产大鼠的改善作用及机制. 中国药房. 2024(21): 2629-2633 .
    23. 郭宇菁，张洁，梁静，潘虹，张铄，王素娟. 益气通腑汤联合乌司他丁对脓毒症胃肠功能障碍患者胃肠激素、肠道菌群和肠屏障标记物的影响. 现代生物医学进展. 2024(20): 3894-3896 .

    Other cited types(22)

Catalog

    Get Citation
    PDF
    XML
    Article views (667) PDF downloads (486) Cited by(45)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：279191

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return